Recce Pharmaceuticals Secures China Patent for Lead Anti-Infectives, Strengthening Global IP Strategy
Recce Pharmaceuticals secures Chinese patent acceptance for its flagship anti-infective compounds, expanding its global IP footprint into the world’s second-largest pharmaceutical market.

( Image: ACB News)
█ ACB News Cathy
SYDNEY, 27 May 2025 – Recce Pharmaceuticals Ltd (ASX: RCE), an Australian biotech developing next-generation synthetic anti-infectives, has received official notification from the China National Intellectual Property Administration (CNIPA) confirming the acceptance of its core Patent Family 4, valid until 2041.
The newly accepted patent covers RECCE® 327 and RECCE® 529, including their manufacturing processes, therapeutic applications for bacterial and viral infections, and multiple delivery formats (oral, injection, transdermal, aerosol, etc.).
This is Recce’s fifth Patent Family 4 grant, following approvals in Australia, Canada, Israel, and Japan. Additional international applications under the Patent Cooperation Treaty (PCT) are under review.
CEO James Graham welcomed the decision, stating it marks a significant expansion of Recce’s global IP portfolio into China, the world’s second-largest pharmaceutical market, where the antibiotic sector alone is valued at US$4.09 billion and forecast to grow at a 5.7% CAGR through 2030.
Recce’s pipeline includes:
● R327: IV/topical therapy for drug-resistant bacterial infections
● R435: Oral antibacterial
● R529: Antiviral therapy
All three compounds have been recognised by the WHO and the FDA, with R327 receiving QIDP status, Fast Track designation, and 10-year post-approval market exclusivity.
Recce owns and operates its own automated manufacturing facility in Australia, supporting current clinical trials and future commercial supply.
This patent marks a key step in Recce’s global commercialisation strategy and its efforts to combat the global threat of antimicrobial resistance.
Copyright Notice:
ACB News reserves full copyright over all articles explicitly marked as "original" content.
No media outlet, corporate website, platform, or app within Australia may reproduce, excerpt, adapt, or republish such content in any form without prior written authorization from ACB News.
Any unauthorized use or reproduction—including via third-party platforms—will be considered an infringement. ACB News reserves the right to pursue legal action against any such violations.
相关阅读
免责声明:本网站信息仅供一般参考,不构成投资或财务建议。虽力求准确与完整,但不保证信息的准确性、完整性或时效性。投资有风险,决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。
热门点击
-
- 冠心病造影软件公司Artrya(ASX:AYA)签下首个美国主动询单客户 五年合同最低价值50万美元
-
- 踩准煤价上行周期 New Hope(ASX:NHC)吞并新州Malabar 瞄准1900万吨产能目标
-
- 澳女首富Gina Rinehart与中国合作投资方挂牌出售昆州大型牧牛场
-
- 反洗钱疑报破千 监管情报流加速 AUSTRAC扩权穿透房地产链条 “7亿澳元购房”盲区随改革收敛
-
- 从矿山到使命 关键矿产重塑地缘战略格局——IMARC 2026国际矿业与资源大会核心议题前瞻(1)
-
- 低资本撬动高回报: Lithium Plus Minerals(ASX:LPM)Lei锂项目概略研究指向75.4%税后IRR与1.8年资本回收期
-
- 澳国民银行启动大规模重组 拟裁员最多2500人约占员工总数6%
-
- 【澳洲锂矿板块深度观察(3)】全球锂供应增长预测下调 澳洲矿山扩产与南美、非洲新增产能重塑产业格局
-
- 11月加息概率陡升!货币政策趋鹰、通胀预期脱锚、房地产深V调整 澳洲经济面临罕见宏观“夹击”
-
- 数据中心运营商NEXTDC(ASX: NXT) 受墨尔本M3项目供电延误拖累大幅下调业绩指引 股价暴跌四成
-
- 澳洲矿业并购与融资活动旺盛 推动本地精品投行及经纪商业绩大幅增长
-
- 转向评估开发!TMK Energy(ASX:TMK)获蒙古监管方确认天然气发现 Gurvantes XXXV启动开采许可流程
-
- 【异动股】澳鹏Appen(ASX:APX)中报出炉股价大幅跳水 全球业务持续失血 中国市场担当增长引擎
-
- 中澳高层深圳会晤 澳方聚焦牛肉贸易摩擦与双边经贸安排
-
- 【异动股】新莱特乳业Synlait Milk (SM1)FY26业绩出炉:净亏损7540万背后 复苏信号已现




